ArticleNeoplasia (New York, N.Y.)2010
ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression.
Article in Neoplasia (New York, N.Y.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Pooled it
- PTEN, ERG, SPINK1, and TFF3 Status and Relationship in a Prostate Cancer Cohort from Jordanian Arab Population.Medicina (Kaunas, Lithuania) · 2024Article
- Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms.Cancer drug resistance (Alhambra, Calif.) · 2020Review
- Exosomes Derived from miR-143-Overexpressing MSCs Inhibit Cell Migration and Invasion in Human Prostate Cancer by Downregulating TFF3.Molecular therapy. Nucleic acids · 2019Article
- Tales from topographic oceans: topologically associated domains and cancer.Endocrine-related cancer · 2019Review
- Combined loss of TFF3 and PTEN is associated with lethal outcome and overall survival in men with prostate cancer.Journal of cancer research and clinical oncology · 2019Article
- Genome-Based Classification and Therapy of Prostate Cancer.Diagnostics (Basel, Switzerland) · 2018Review
- Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.International journal of molecular sciences · 2017Article
- Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network.Genome biology · 2017Article
- Review
- The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.International journal of medical sciences · 2017Article
- A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors.Cell reports · 2016Article
- The oncogene ERG: a key factor in prostate cancer.Oncogene · 2016Review
- Article
- ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Article
- ERG induces taxane resistance in castration-resistant prostate cancer.Nature communications · 2014Article
- The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer.Nature communications · 2014Article
- ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer.Prostate cancer and prostatic diseases · 2014Article
- Androgen receptor and gene network: Micromechanics reassemble the signaling machinery of TMPRSS2-ERG positive prostate cancer cells.Cancer cell international · 2014Review
- Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions.Molecular cancer research : MCR · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 3 countries.
Funding
Abstract
To elucidate the role of ETS gene fusions in castration-resistant prostate cancer (CRPC), we characterized the transcriptome of 54 CRPC tumor samples from men with locally advanced or metastatic disease. Trefoil factor 3 (TFF3) emerged as the most highly differentially regulated gene with respect to ERG rearrangement status and resistance to hormone ablation therapy. Conventional chromatin immunoprecipitation (ChIP)-polymerase chain reaction and ChIP followed by DNA sequencing (ChIP-seq) revealed direct binding of ERG to ETS binding sites in the TFF3 promoter in ERG-rearranged prostate cancer cell lines. These results were confirmed in ERG-rearranged hormone-naive prostate cancer (HNPC) and CRPC tissue samples. Functional studies demonstrated that ERG has an inhibitory effect on TFF3 expression in hormone-naive cancer but not in the castration-resistant state. In addition, we provide evidence suggesting an effect of androgen receptor signaling on ERG-regulated TFF3 expression. Furthermore, TFF3 overexpression enhances ERG-mediated cell invasion in CRPC prostate cancer cells. Taken together, our findings reveal a novel mechanism for enhanced tumor cell aggressiveness resulting from ERG rearrangement in the castration-resistant setting through TFF3 gene expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.